Advancing Education on Biosimilars Act of 2021
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Advancing Education on Biosimilars Act of 2021
This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)
The FDA may also maintain and operate a website to provide educational materials about biological products.
Referred to the Subcommittee on Health.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 1873: Advancing Education on Biosimilars Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-HR-1873/
"H.R. 1873: Advancing Education on Biosimilars Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-1873/.
H.R. 1873, 117th Cong. (2026), https://openamerica.io/bill/117-HR-1873/.
[H.R. 1873: Advancing Education on Biosimilars Act of 2021](https://openamerica.io/bill/117-HR-1873/)